Sonrotoclax

Brand names: Beqalzi · Active ingredient: Sonrotoclax

In short: BEQALZI is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor. This indication is approved under accelerated approval based on response rate and durabi

Forms & strengthsTablet Strength | Description 1 mg | Purple, oval, film-coated tablets with 1 debossed on one side. 5 mg | Purple, oval, film-coated tablets with 5 debossed on one side. 20 mg | Purple, oblong, film-coated tablets with 20 debossed on one side. …
LabelBeOne Medicines USA, Inc.
Label updatedSep 28, 2026

What is Sonrotoclax used for?

BEQALZI is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.

This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) .

Sonrotoclax dosage

BEQALZI can cause tumor lysis syndrome (TLS), especially during the ramp-up phase or during restart after a dosage interruption .

Initiate BEQALZI with a dose ramp-up. For dose interruption lasting greater than 7 days, adjust the restart BEQALZI dose as instructed .

Assess patient risk for TLS and whether hospitalization for monitoring is warranted.

Initiate prophylactic hydration and anti-hyperuricemics before the first dose of BEQALZI and continue as appropriate.

Correct pre-existing electrolyte abnormalities before the first dose.

Monitor blood chemistries closely .

BEQALZI dosing begins with a 4-week ramp-up. The ramp-up dosing schedule is designed to gradually reduce tumor burden (debulk) and decrease the risk of TLS.

4-Week Dose Ramp-Up Schedule

Administer BEQALZI orally once daily, according to the ramp-up dosing schedule shown in Table 1.

Week Number | Days | Daily Dose | Number of Tablets per Dose

Week 1 | Days 1 to 3 | 1 mg | One 1 mg tablet

Days 4 to 7 | 2 mg | Two 1 mg tablets

Week 2 | Days 1 to 3 | 5 mg | One 5 mg tablet

Days 4 to 7 | 10 mg | Two 5 mg tablets

Week 3 | Days 1 to 3 | 20 mg | One 20 mg tablet

Days 4 to 7 | 40 mg | Two 20 mg tablets

Week 4 | Days 1 to 3 | 80 mg | One 80 mg tablet

Days 4 to 7 | 160 mg | Two 80 mg tablets

The Starter Pack provides the first 4 weeks of BEQALZI according to the ramp-up schedule .

Target Dose Week 5 and Beyond

After completion of the 4-week ramp-up phase, the recommended dosage of BEQALZI is 320 mg (four 80 mg tablets) taken orally once daily until disease progression or unacceptable toxicity.

Dosing after treatment interruption greater than 7 days is described in Table 3 .

Table 2 provides recommended BEQALZI dosage modifications for adverse reactions.

Table 3 provides temporary dose modifications upon restart after dose interruptions lasting more than 7 days.

Table 4 provides recommended modifications to the target dose after adverse reactions are resolved.

Adverse ReactionAdverse reactions were graded using NCI CTCAE version 5.0. | Occurrence | Dosage Modification

Tumor Lysis Syndrome

Any blood chemistry changes or symptoms suggestive of TLS | Any | Interrupt BEQALZI. Upon resolution of lab abnormalities, resume BEQALZI.

For interruptions lasting 7 days or less, resume planned dosing.

For interruptions lasting more than 7 days, see Table 3 for dosage when resuming treatment.

Hematologic Toxicity

Grade ≥3 febrile neutropenia | First | Interrupt BEQALZI. Resume BEQALZI at the same dose upon recovery.

Second and subsequent | Interrupt BEQALZI.A maximum of 2 dose reductions is recommended.

Upon recovery to Grade 1 or baseline level, resume BEQALZI and follow dose reduction guidelines in Table 3 and Table 4. …

How to take Sonrotoclax — instructions & advice from the label

Advise patients to read the FDA-approved patient labeling (Medication Guide).

Tumor Lysis Syndrome

Advise patients of the potential risk of TLS, particularly at treatment initiation, during the ramp-up phase, and with restarting the dose after an interruption, and to immediately report any signs and symptoms associated with this event (fever, chills, nausea, vomiting, confusion, shortness of breath, seizure, irregular heartbeat, decreased urination, unusual tiredness, muscle cramps or twitches) to their healthcare provider (HCP) for evaluation .

Advise patients to be adequately hydrated when taking BEQALZI to reduce the risk of TLS. The recommended volume is 6 to 8 glasses (approximately 1.5 to 2 liters) of water daily starting 1-2 days before taking BEQALZI, on the day of the first dose, on any day the dose is increased until target dose is reached, and at restart, if applicable .

Advise patients of the importance of keeping scheduled appointments for blood work or other laboratory tests .

Advise patients that it may be necessary to take BEQALZI in the hospital or medical office setting to allow monitoring for TLS. …

Warnings & precautions

Do not take this medicine if: Concomitant use of sonrotoclax with strong CYP3A inhibitors at initiation and during the ramp-up phase is contraindicated in patients due to the potential for increased risk of tumor lysis syndrome .

BEQALZI can cause serious or life-threatening tumor lysis syndrome (TLS). BEQALZI can cause rapid reduction in tumor and changes in blood chemistries consistent with TLS that require prompt management. This can occur as early as 4 hours after the first dose, at any dose increases, and upon restart following dosage interruption. Laboratory or clinical TLS occurred in 7% of the 115 patients with MCL who followed the recommended dose ramp-up.

Risk factors for TLS include higher tumor burden such as bulky lymphadenopathy or lymphocytosis and reduced renal function.

Assess all patients for TLS risk and provide appropriate prophylaxis, including hydration and anti-hyperuricemics begun prior to the first dose of BEQALZI. Correct relevant chemistry abnormalities prior to starting BEQALZI. Consider hospitalization with intravenous hydration and monitoring and employ more frequent monitoring for patients with high TLS risk. Monitor blood chemistries and manage abnormalities promptly. Interrupt dosing if needed; when restarting BEQALZI, follow the dose modification guidance .

Concomitant use of sonrotoclax with strong or moderate CYP3A inhibitors increases sonrotoclax exposure, which may increase the risk of TLS at initiation and during the ramp-up phase .

BEQALZI can cause fatal or serious infections . Among patients who received BEQALZI at the recommended dosage in the clinical trial, serious infections occurred in 14% of patients and Grade 3 or higher infections in 17%, with fatal infections in 2.6% of patients. The most common Grade 3 or greater infection was pneumonia (10%). Monitor for signs and symptoms of infection and treat appropriately. …

Sonrotoclax side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Tumor Lysis Syndrome

Serious Infections

Neutropenia

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Mantle Cell Lymphoma

The safety of BEQALZI was evaluated in 115 adult patients with previously treated MCL in a single-arm, multicenter clinical trial, BGB-11417-201 (NCT05471843) . The trial required prior receipt of anti-CD20–based therapy and a BTK inhibitor. The trial excluded patients on moderate or strong CYP3A inhibitors or strong CYP3A inducers and required an absolute neutrophil count (ANC) ≥1000/mm3; platelets ≥75,000/mm3; creatinine clearance ≥50 mL/min; AST and ALT ≤3 × upper limit of normal (ULN); and serum total bilirubin ≤2 × ULN.

Patients received BEQALZI 320 mg orally once daily following completion of a 4-week ramp-up dosing schedule. Of the 115 patients who received BEQALZI, 52% were exposed for at least 6 months and 34% were exposed for at least 1 year.

Serious adverse reactions were reported in 37% of patients who received BEQALZI, most frequently (≥2%) from pneumonia (10%). Fatal adverse reactions occurred in 4.3% of patients, including from pneumonia (2.6%) and sudden death (1.7%). …

Drug interactions

Strong or Moderate CYP3A Inhibitors

Concomitant use of strong CYP3A inhibitors during the initiation and ramp-up phase with BEQALZI is contraindicated. After the ramp-up phase, reduce the target dose of BEQALZI as in Table 5 .

For dose modifications of sonrotoclax with moderate CYP3A inhibitors, see Dosage and Administration (2.4).

Sonrotoclax is a CYP3A substrate . Concomitant use with strong and moderate CYP3A inhibitors increase sonrotoclax exposure , which may increase the risk of BEQALZI adverse reactions.

Strong or Moderate CYP3A Inducers

Avoid concomitant use of strong or moderate CYP3A inducers with BEQALZI.

Sonrotoclax is a CYP3A substrate . Concomitant use with strong CYP3A inducers decreases sonrotoclax exposure , which may reduce effectiveness of sonrotoclax.

About this medicine

BEQALZI tablets contain sonrotoclax, a B-cell lymphoma 2 (BCL-2) inhibitor. The molecular formula of sonrotoclax is C49H59N7O7S and the chemical name is N-[4-({[(1r,4r)-4-hydroxy-4-methylcyclohexyl]methyl}amino)-3-nitrobenzene-1-sulfonyl]-4-(2-{(2S)-2-[2-(propan-2-yl)phenyl]pyrrolidin-1-yl}-7-azaspiro[3.5]nonan-7-yl)-2-[(1H-pyrrolo[2,3- b]pyridin-5-yl)oxy]benzamide.

The molecular weight of sonrotoclax is 890.11 Daltons.

Sonrotoclax has the following structure:

BEQALZI tablets for oral use contain 1, 5, 20, or 80 mg of sonrotoclax. Each tablet contains the following inactive ingredients: anhydrous dibasic calcium phosphate, colloidal silicon dioxide (20 and 80 mg only), croscarmellose sodium, hydroxypropyl methylcellulose acetate succinate, magnesium stearate, microcrystalline cellulose, talc (20 and 80 mg only). The tablet film coating contains FD&C Blue No. 1/brilliant blue FCF aluminum lake, FD&C Red No. 40/allura red ac aluminum lake, polyethylene glycol, polyvinyl alcohol, soy lecithin, talc, and titanium dioxide. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ff684558-e9cb-46de-a8bf-f4d79093df7a. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate